Corcept Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Corcept Therapeutics sits in the top decile of US sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count).
Corcept Therapeutics: 54 sponsored US clinical trials, 6 recruiting.
Corcept Therapeutics sponsors 54 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 37 completed. 12 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cushing Syndrome, with 3 trials.
Top-decile sponsor footprint
Corcept Therapeutics ranks in the top decile of sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
37 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
54 total, page 1 of 2
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
NCT06947304
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324
Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
NCT07240116
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
NCT06829537
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT06928779
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
NCT06495944
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT05772169
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
NCT05712265
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
NCT05347979
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT05320146
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
NCT05553470
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT05117489
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
NCT04795479
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT03823703
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
NCT04373265
A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
NCT06094738
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
NCT04524403
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
NCT04308590
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
NCT06094725
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
NCT03818256
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
NCT03697109
A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
NCT03540836
Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
NCT03512548
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
NCT03457597
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03437941
Relacorilant Food Effect Study in Healthy Subjects
NCT03442621
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
NCT03379363
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
NCT03258372
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
NCT03259542
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
NCT06094790
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
NCT02922257
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
NCT02804750
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
NCT02762981
A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
NCT06094712
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
NCT02014337
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
NCT01371565
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00936741
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
NCT00796783
A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
NCT00752843
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCT00637494
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00569582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 11 |
| Phase 3 | 11 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Corcept Therapeutics pipeline
6 recruiting of 54 indexed (11% open); 37 completed (69%).
Phase mix: 12 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Cushing Syndrome (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Corcept Therapeutics: open-pipeline peers nationwide
Peers matched on 54 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Corcept Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 54 trials (± recruiting share)
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
- Auburn University · 54 trials · 24% recruiting
- Brooke Army Medical Center · 54 trials · 11% recruiting
- Pharmacyclics · 54 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this Corcept Therapeutics page
54 registered trials is a research-attention snapshot, not an endorsement of Corcept Therapeutics or any single study.
- 6 of Corcept Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cushing Syndrome is the condition Corcept Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cushing Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Corcept Therapeutics pipeline card: 54 registered trials from official public datasets.Report a data error.